经动脉灌注化疗辅助静脉化疗对无法手术晚期胃癌患者的治疗效果#br#

目的研究经动脉灌注化疗辅助静脉化疗对无法手术的晚期胃癌患者的治疗效果。方法选取青岛市市立医院消化内科2014年6月—2017年7月收治的晚期胃癌患者104例，其中60例采用全身静脉化疗（静脉组），44例采用经动脉灌注化疗联合全身静脉化疗（联合组）；比较两组化疗后的效果、化疗期间的不良反应及化疗前后患者血清癌胚抗原（CEA）、糖类抗原125（CA125）、糖类抗原19 9（CA19 9）、组织多肽特异性抗原（TPS）水平，比较两组的2年生存率及总生存时间。结果联合组患者的总有效率（7500%）高于静脉组（5333%），差异有统计学意义（P<005）；化疗前，联合组与静脉组的血清CEA、CA125、CA19 9、TPS水平差异无统计学意义（P>005）；化疗后，两组患者的血清CEA、CA125、CA19 9、TPS水平均较本组化疗前降低，且联合组低于静脉组，差异有统计学意义（P<005）；两组患者的骨髓抑制、血红蛋白降低、血小板减少、恶心呕吐、腹泻、口腔黏膜炎、肝肾损伤的发生程度差异无统计学意义（P>005）；两组2年随访失访率、2年生存率差异无统计学意义（P>005）；联合组的总生存时间（19个月）长于对照组（12个月），差异有统计学意义（P<005）。结论经动脉灌注化疗辅助静脉化疗对延长无法手术晚期胃癌患者的生存期有一定益处。

Effect of Arterial Infusion Chemotherapy on Prolonging Survival of Inoperable Gastric Cancer Patients

Objective To investigate the therapeutic effect of transarterial infusion chemotherapy-assisted intravenous chemotherapy on patients with advanced gastric cancer who cannot be operated. Methods A total of 104 patients with advanced gastric cancer admitted to our hospital were selected as the research objects. Among them, 60 patients received systemic intravenous chemotherapy (intravenous group), and 44 patients received intra-arterial infusion chemotherapy combined with systemic intravenous chemotherapy (combined group); Effect, side effects during chemotherapy, changes in serum carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), carbohydrate antigen 199 (CA199), tissue polypeptide specific antigen (TPS) before and after chemotherapy, and 2 years survival Rate and overall survival time. Results The total effective rate of patients in the combination group was 75.00% higher than that in the intravenous group of 53.33%, and the difference was statistically significant (P<0.05); before chemotherapy, the serum CEA, CA125, CA199, and TPS levels of the combination group and the intravenous group were compared, The difference was not statistically significant (P>0.05); after chemotherapy, the levels of serum CEA, CA125, CA199, and TPS in the two groups were significantly lower than those before chemotherapy (P<0.05). The serum CEA, CA125, and TPS levels in the combined group CA199 and TPS levels were lower than the intravenous group (P<0.05); there was no statistical difference in the incidence of bone marrow suppression, hemoglobin reduction, thrombocytopenia, nausea and vomiting, diarrhea, oral mucositis, liver and kidney damage in the combined group and the intravenous group. Significance (P>0.05); the two-year follow-up loss rate and the 2-year survival rate of the combination group and the intravenous group were not statistically significant (P>0.05); the overall survival time of the combination group was 19.0 months longer than that of the control group At 12.0 months, the difference was statistically significant (P<0.05). Conclusion Intra-arterial infusion chemotherapy-assisted intravenous chemotherapy has a certain effect on the prolongation of survival in patients with advanced gastric cancer who cannot be operated.